WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced it will hold its 2025 R&D Day in Midtown, New York, on Tuesday, October 14, at 8:00 a.m. ET. The event will highlight the company’s progress in developing therapies aimed at unmet needs in immuno-inflammatory markets.
The program will feature presentations from Aclaris leadership alongside invited experts, including Zuzana Diamant, MD, PhD, FERS, pulmonologist and clinical pharmacologist at University Medical Center Groningen, and Michael C. Cameron, MD, FAAD, assistant clinical professor of dermatology at Mount Sinai in New York. Together, they will review the company’s pipeline, with a focus on kinase and immune pathway inhibitors targeting validated immune mechanisms.
Planned discussion topics include Aclaris’ development of small- and large-molecule product candidates, its proprietary discovery technology platform designed to target previously inaccessible areas of the kinome, and updates on its ITK inhibition and TSLP franchises. Leadership will also provide updates on ongoing and planned clinical trials, including monoclonal and bispecific antibody programs. A live question-and-answer session will follow.
A live webcast will be accessible through the events page of Aclaris’ website and archived there for at least 30 days.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.